For decades, women have received mixed messages about menopausal hormone therapy.
Many women experiencing hot flashes, night sweats, sleep disruption, mood changes, vaginal symptoms, decreased sexual function, brain fog, and other symptoms of menopause have been hesitant to consider hormone therapy because of concerns about long-term health risks.
A newly published 2026 study in Obstetrics & Gynecology adds an important piece to the conversation.
Researchers evaluated the cost-effectiveness and long-term health outcomes of menopausal hormone therapy in symptomatic women beginning treatment around age 50.
Their conclusion was striking: menopausal hormone therapy was not only cost-effective—it was less expensive overall than no hormone therapy while producing more quality-adjusted years of life.
What Did the Study Find?
The researchers modeled two commonly used treatment approaches over five years:
- Transdermal estradiol for women without a uterus
- Transdermal estradiol combined with micronized progesterone for women with a uterus
They then compared these treatment strategies with no menopausal hormone therapy.
For every 10,000 women modeled over their lifetimes, estradiol therapy was associated with approximately $135 million lower healthcare costs and more than 33,000 additional quality-adjusted life years compared with no hormone therapy.
The estradiol group was also associated with:
- 259 fewer cases of atherosclerotic cardiovascular disease
- 181 fewer hip fractures
- 105 fewer cases of colon cancer
- 647 fewer deaths
The estradiol-plus-micronized-progesterone group demonstrated similarly favorable overall results, including approximately $128 million in lower healthcare costs and more than 33,000 additional quality-adjusted life years compared with no hormone therapy.
The researchers concluded that menopausal hormone therapy was cost-effective for typical symptomatic women beginning treatment around age 50 and using therapy for five years.
It is important to note that this was a health-economic modeling study, not a clinical trial proving that every woman who uses hormone therapy will experience these exact outcomes.
Still, the findings are meaningful because they support a broader shift in the way we think about menopausal hormone therapy.
Rather than viewing hormone treatment only as a way to manage hot flashes or night sweats, research continues to explore its relationship to quality of life, bone health, cardiovascular health, healthcare utilization, and long-term outcomes.
Hormone Therapy Has Changed
One of the most important parts of the modern hormone conversation is understanding that all hormone therapy is not the same.
The formulation matters.
The dose matters.
The route of administration matters.
The timing of treatment matters.
And most importantly, the individual patient matters.
A woman’s age, symptoms, health history, uterus status, breast-health history, cardiovascular risk factors, hormone levels, lifestyle, and personal goals can all influence which treatment strategy may be most appropriate.
The new study specifically evaluated transdermal estradiol and micronized progesterone.
That is important because modern hormone therapy differs significantly from some of the hormone formulations used in older research that shaped public perception of menopausal hormone therapy for decades.
Today, menopause care is increasingly focused on individualized risk assessment and shared decision-making rather than assuming that hormone therapy is universally good or universally bad.
One Important Limitation: This Study Did Not Evaluate Every Hormone or Delivery Method
While this study is encouraging, it is equally important to recognize what it did—and did not—evaluate.
The researchers specifically modeled transdermal estradiol and micronized progesterone.
They did not evaluate:
- Testosterone therapy
- Pellet therapy
- Injectable hormone therapy
- Topical testosterone
- Other individualized hormone combinations
- Longer-term individualized hormone optimization strategies
That means this study should not be interpreted as a comparison of all available hormone therapies.
Instead, it tells us that the specific estrogen and progesterone regimens included in the study were associated with favorable cost-effectiveness and long-term modeled outcomes compared with no treatment.
At Revitalizing Health & Hormones, we believe that distinction matters because hormone optimization can involve much more than estrogen and progesterone alone.
Testosterone Is Part of the Hormone Conversation, Too
Women naturally produce testosterone throughout their lives.
While testosterone is often thought of primarily as a male hormone, it also plays an important role in female physiology.
Testosterone levels can decline with age, and for appropriately selected women, testosterone may be considered as part of a broader hormone-optimization strategy.
Depending on the individual, testosterone may be discussed in relation to symptoms such as changes in sexual function, energy, motivation, strength, body composition, and overall sense of well-being.
Testosterone therapy is not appropriate for every woman, and treatment decisions should always be individualized.
However, the fact that testosterone was not included in this study is worth noting.
The analysis therefore does not tell us how including testosterone as part of a more comprehensive hormone strategy might affect quality of life, long-term outcomes, healthcare utilization, or overall cost-effectiveness.
That creates an important opportunity for future research.
What About Pellet Therapy?
Pellet therapy was also not included in this study.
At Revitalizing Health & Hormones, pellet therapy is one of the hormone-delivery options we offer to appropriately selected patients.
Hormone pellets are placed beneath the skin and gradually release hormone over time.
For many patients, this can offer a convenient, longer-acting approach to hormone therapy without the need for daily application or frequent dosing.
Depending on the treatment plan, pellet therapy may include hormones such as estradiol or testosterone.
For some patients, the appeal of pellets is their convenience and their ability to provide sustained hormone delivery over several months.
As with any form of hormone therapy, pellet treatment requires thoughtful patient selection, appropriate dosing, monitoring, and follow-up.
It is also important to recognize that this new study did not compare transdermal hormone therapy with pellet therapy.
Because of that, the findings should not be interpreted to mean that one delivery method is universally superior to another.
Rather, the study strengthens the broader conversation around the potential value of appropriately prescribed hormone therapy while leaving open important questions about how other treatment modalities may perform.
Future research directly comparing hormone delivery methods—including patches, creams, injections, oral therapies, and pellets—would be valuable.
Why Individualized Hormone Therapy Matters
This study also reinforces something we see every day in clinical practice:
There is no single hormone protocol that is right for every woman.
Two women may both be 50 years old and experiencing menopausal symptoms, yet have completely different medical histories, symptoms, goals, laboratory findings, and treatment preferences.
One woman may benefit from estrogen alone.
Another may need estrogen and progesterone.
Another may be experiencing symptoms that lead to a conversation about testosterone.
And another may prefer pellet therapy because of its longer-acting delivery and convenience.
That is why individualized care matters.
At Revitalizing Health & Hormones, We Look at the Whole Picture
At Revitalizing Health & Hormones, our approach to hormone care begins with a simple principle:
Hormone therapy should be individualized to the patient—not prescribed according to a one-size-fits-all formula.
That means looking beyond a single symptom or laboratory value.
Depending on the individual, hormone therapy may involve estrogen, progesterone, testosterone, or a combination of therapies.
We also consider different methods of hormone delivery, including options such as topical therapy, injections, and pellet therapy when clinically appropriate.
Our team evaluates:
- Symptoms
- Health history
- Laboratory findings when clinically appropriate
- Menstrual and menopausal history
- Risk factors
- Treatment goals
- Previous hormone therapy
- Patient preferences
- Response to treatment over time
For patients interested in pellet therapy, our providers discuss how treatment works, expected duration, monitoring, potential benefits, possible risks, and alternative hormone-delivery methods.
Our goal is not simply to make a laboratory number look better.
It is to help patients feel better, function better, and make informed decisions about their long-term health.
The Bigger Message From This Study
Perhaps the most important takeaway from this research is that the conversation around menopause continues to evolve.
For years, many women were told they simply needed to tolerate menopausal symptoms.
Others were frightened away from hormone therapy altogether.
Modern research provides a much more nuanced picture.
For appropriately selected women, hormone therapy can play an important role in managing menopausal symptoms and improving quality of life.
This new research suggests that the potential value of treatment may extend even further.
In this model, menopausal hormone therapy was associated with:
- Greater quality-adjusted life expectancy
- Lower lifetime healthcare costs
- Fewer hip fractures
- Fewer cardiovascular events
- Fewer deaths overall
That is significant.
And it raises an equally important question:
If estrogen and progesterone therapy alone demonstrated these results, what might we learn as future research evaluates more individualized approaches—including testosterone and additional delivery methods such as pellet therapy?
Those are questions worth studying.
Women Deserve Better Menopause Care
Menopause is not a disease.
But women should also not be expected to suffer unnecessarily through years of disruptive symptoms when treatment options may be available.
The conversation around hormone therapy is becoming more sophisticated, individualized, and evidence-based.
Women deserve the opportunity to understand their options, discuss the potential benefits and risks, and make informed decisions about their own health.
At Revitalizing Health & Hormones, that is exactly the type of conversation we want our patients to have.
Ready to Talk About Your Hormones?
If you are experiencing symptoms of perimenopause or menopause, our team at Revitalizing Health & Hormones can help you understand your options.
We take a comprehensive, individualized approach to hormone health and help patients evaluate their symptoms, health history, laboratory findings, treatment preferences, and available therapies.
Your treatment options may include estrogen, progesterone, testosterone, pellet therapy, or other individualized approaches depending on your needs.
Schedule a consultation with Revitalizing Health & Hormones to learn more about your hormone health and whether hormone therapy may be appropriate for you.
Research Discussed
Gill E, Zeng W, Shvartsman K, Brown J. Cost-Effectiveness Analysis of Menopausal Hormone Therapy. Obstetrics & Gynecology. 2026. DOI: 10.1097/AOG.0000000000006404.
Medical Disclaimer
This article is intended for educational purposes only and does not constitute individualized medical advice. Hormone therapy has potential benefits, risks, and contraindications. Treatment decisions should be made in consultation with a qualified healthcare professional based on the individual patient’s health history, symptoms, risk factors, and goals.
